

DAFTAR PUSTAKA

- Antman, E., Bassand, J. P., Klein, W., Ohman, M., Sendon, J. L. L., Rydén, L., & Tendera, M. 2000. *Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology/American College of Cardiology Committee. Journal of the American College of Cardiology*, 36(3), 959-969.
- Antman, E.M., Anbe, D.T., Armstrong, P.W., Bates, E.R., Green, L.A., Hand, M., Hochman, J.S., Krumholz, H.M., Kushner, F.G., Lamas, G.A. and Mullany, C.J., 2004. *ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Journal of the American College of Cardiology*, 44(3), pp.671-719.
- Anderson PO, Knoblen JE, Troutman WG. 2002. *Handbook of Clinical Drug Data 10th Edition*. New York: Medical Publishing Division.
- Baxter, Editor, 2008. *Stockley's Drug Interaction. Eight Edition*. London: Pharmaceutical Press.
- Benowitz, Neal L. 2003."Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment." *Progress in cardiovascular diseases* 46.1: 91-111.
- Bjartveit, K., & Tverdal, A. 2005. Health consequences of smoking 1–4 cigarettes per day. *Tobacco control*, 14(5), 315-320.
- Braundwald E, Elliot M, Antman, David A, Morrow. 2012. Braundwald's Heart Disease, in (Braundwald Ninth Eds). *ST-Segment Elevation Myocardial Infarction: Management*. Philadelphia: Saunders Elsevier, pp 1111-55.
- British National Formulary. 2008. BNF 56. London:BMJ group.
- Brodde OE, Kroemer HK. 2003. *Drug-drug Interaction of beta-adrenoreceptor blockers*. *Arzneimittelforschung*. Vol 53:814-822.
- Cannon, C. P., Bahit, M. C., Haugland, M. J., Henry, T. D., Schweiger, M. J., McKendall, G. R., & Antman, E. M. 2002. *Underutilization of Evidence-Based Medications in Acute ST Elevation Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry*. *Critical pathways in cardiology*, 1(1), 44-52.
- Centers for Disease Control and Prevention. 2010. *How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable*

disease: A report of the surgeon general. Centers for Disease Control and Prevention (US).

Chieffo, A., Buchanan, G. L., Mauri, F., Mehilli, J., Vaquerizo, B., Moynagh, A. 2012. *ACS and STEMI treatment: gender-related issues.* *EuroIntervention*, 8:P27-P3

Delaware Health and Social Services, 2008. *State of Delaware Paramedic Standing Orders: Pharmacology Manual.* Delaware Health and Social Services.

De Luca, G., van't Hof, A. W., Ottervanger, J. P., Hoorntje, J. C., Gosselink, A. M., Dambrink, J. H. E., ... & Suryapranata, H. 2005. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. *European heart journal*, 26(7), 662-666.

Departemen Kesehatan Republik Indonesia. 2013. *Profil Kesehatan Indonesia 2012.* Jakarta: Departemen Kesehatan RI.

Departemen Kesehatan Republik Indonesia. *Pusat Informasi Obat (PIO).* Depkes RI.

Dipiro JT, Talber RL, Yee GC, Matzke GR, Welsh BG, Posey LM. 2005. *Pharmacotherapy Pathophysiologic Approach Sixth Edition.* New York. McGraw-Hill Medical Publishing Division.

FDA. 2011. *Limit Use of 80 mg Simvastatin.* Food and Drug Administration.

French, J. K., Andrews, J., Manda, S. O., Stewart, R. A., McTigue, J. J., & White, H. D. 2002. *Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction.* *American heart journal*, 143(2), 265-271.

Gelber, R. P., Gaziano, J. M., Orav, E. J., Manson, J. E., Buring, J. E., & Kurth, T. 2008. *Measures of obesity and cardiovascular risk among men and women.* *Journal of the American College of Cardiology*, 52(8), 605-615.

Gitawat, Retno. 2008. *Interaksi Obat dan Beberapa Implikasinya.* Media Litbang Kesehatan Vol 8 No 4. Badan Litbangkes: Puslitbang Biomedika dan Farmasi.

Glover, B. M., & Adgey, A. J. 2008. *Acute reperfusion strategies for ST-segment elevation myocardial infarction.* *European heart journal*, 29(5), 571-572.

Gonzalez, A. B; ,Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., & Beeson, W. L. 2010. *Body-mass index and mortality among 1.46 million white adults.* *New England Journal of Medicine*, 363(23), 2211-2219.

Griffin, B.P and Topol, E.J. 2004. *Manual of Cardiovascular Medicine.* United States: Lippincott Williams and Wilkins.

- Kanic, V., Vollrath, M., Naji, F. H., & Sinkovic, A. 2016. *Gender Related Survival Differences in ST-Elevation Myocardial Infarction Patients Treated with Primary PCI*. *International journal of medical sciences*, 13(6), 440.
- Kumar, A., & Cannon, C. P. 2009. *Acute coronary syndromes: diagnosis and management, part I*. In *Mayo Clinic Proceedings* (Vol. 84, No. 10, pp. 917-938). Elsevier.
- Kumar, V., Abbas, A. K., & Aster, J. C. 2013. *Robbins basic pathology*. Elsevier Health Sciences.
- Law, M. R., & Wald, N. J. 2003. *Environmental tobacco smoke and ischemic heart disease*. *Progress in cardiovascular diseases*, 46(1), 31-38.
- Makris, Anastasios, Maria Seferou, and Dimitris P. Papadopoulos. 2010. "Resistant hypertension workup and approach to treatment." *International journal of hypertension* 2011.
- McEvoy, G. K., Snow, E. K., Kester, L., Litvak, K., Miller, J., & Welsh, O. H. 2011. AHFS 2011 Drug Information. *Bethesda, MD: American Society of Health-System Pharmacists*.
- Mendelsohn, Colin. 2013. *Smoking and Cardiovascular Disease*. VOLUME 3, Number 4 *Cardiology today* 23.
- National Institute for Health and Care Excellence. 2013. *Secondary prevention in primary and secondary care for patients following a myocardial infarction*. NICE clinical guideline 172.
- NHS trust. 2012. *Use and monitoring of low Molecular Weight Heparin (LMWH)*. Torbay and Southern Devon Health and Care.
- Notoadmojo, Soekidjo. 2012. *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta.
- Opie, L. H. 2012. *Drug interactions of antihypertensive agents*. *South African Family Practice*, 54(2), S23-S25.
- Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia (PERKI). 2014. *Pedoman Tatalaksana Sindrom Koroner Akut*. Centra Communication.
- Rifqi, Sodiqur. 2012. *Primary Percutaneous Coronary Intervention (Primary PCI)*. *Senjata "Baru" untuk Melawan Serangan Jantung Akut*. *Medica Hospitalia*: Tangerang.
- Schwartz JB, Zipes DP. 2005. *Cardiovascular disease in the elderly*. In: Braunwald, Zipes, Libby, editors. *Heart Disease: A Textbook of Cardiovascular Medicine*. 7th ed. Philadelphia: W.B. Saunders Co; p. 1925-49.

- Senaratne, J. W., & Green, F. R. 2000. *Pathobiology of atherosclerosis*. In: Peter J. Morris, William C. Wood editor. Oxford Textbook of Surgery. 2nd edition. US: Oxford press; 2000: Vol. 3. 23.
- Setiawati. 2007. *Interaksi Obat*. Dalam buku : Sulistia Gan Gunawan, Rianto Setiabudy, Nafriadi, Elysabeth, Editor. *Farmakologi dan Terapi Edisi 5*. Jakarta : Departemen Farmakologi dan Terapeutik FKUI, 862,863,866,872.
- Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., & Gershlick, A. H. 2012. *ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation*. *European heart journal*, ehs215.
- Sudoyo, AW, Setiyohadi B, Alwi, I, Simadibrata, M, Setiati, S. 2006. *Buku Ajar Ilmu Penyakit Dalam Jilid II edisi V*. Jakarta: Interna Publishing.
- Sweetman, S. C. 2009. *Martindale: the complete drug reference*. Pharmaceutical press.
- Sydell and Arnold Miller Family Heart & Vascular Institute. 2009. *Coronary Artery Disease Treatment Guide*. Cleveland Clinic.
- Tatro, Editor, 2009. *Drug Interaction Facts. Fifth Edition*. United States of America: Wolters Kluwer Company.
- Teo, K. K., Ounpuu, S., Hawken, S., Pandey, M. R., Valentin, V., Hunt, D., & Zhang, X. 2006. *Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study*. *The lancet*, 368(9536), 647-658.
- Thanacody, 2012. *Drug Interaction*. Dalam buku: Walker R dan Whittlesea, Editor. *Clinical Pharmacy and Therapeutics*. Fifth Edition. London : Churchill Livingstone Elsevier, 50,51,57,58,59,119-131.
- Tierney LM, McPee SJ, Papadakis MA. 2002. *Diagnosis dan Terapi Kedokteran (Penyakit Dalam)*. Jakarta: Salemba Medika.
- Walsh, FO and Wilson, P. 2008. *Hurst 12th Edition. The Heart. Mc Graw-Hill Companies*.
- Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J, Huber K, Kala P, Klineva M, Kristensen SD, Ludman P, Ferre JM, Merkely B, Milicic D, Morais J, Noc M, Opolski G, Ostojic M, Radovanovic D, De Servi S, Stenestrand U, Studencan M, Tubaro M, Vasiljevic Z, Weidinger F, Witkowski A, Zeymer U. 2010. *Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries*. *European Heart Journal* ;31:943–957

Yuliani, Eva. 2013. *Interaksi Obat Pada Pasien Geriatri yang Menderita Penyakit Jantung dan Penyakit Dalam di Instalasi Rawat Inap Bangsal Teratai Rumah Sakit Umum Pusat (RSUP) Fatmawati Periode Oktober-November 2012*. (Skripsi). Jakarta.

Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., & Lisheng, L. 2004. *Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet*, 364(9438), 937-952.

